SELLAS Life Sciences Group, Inc. (SLS)
| Market Cap | 135.88M |
| Revenue (ttm) | 7.60M |
| Net Income (ttm) | -15.02M |
| Shares Out | 14.88M |
| EPS (ttm) | -1.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $8.56 |
| Previous Close | $8.69 |
| Change ($) | -0.13 |
| Change (%) | -1.50% |
| Day's Open | 8.72 |
| Day's Range | 8.43 - 8.84 |
| Day's Volume | 245,093 |
| 52-Week Range | 1.76 - 19.38 |
SELLAS Life Sciences Group Inc. (NASDAQ: SLS) shares were trading lower Wednesday after the company released updated clinical and initial immunobiological data from a Phase 1/2 clinical trial ofits lead...
Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up
Updated Data Show Median Overall Survival of 35.4 Weeks in Patients Treated With Combination Therapy for at Least One Month – Median Overall Survival in Relapse/Refractory Patients with Standard of Care...
NEW YORK, June 22, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer...
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) shares rallied Tuesday as retail traders try to push the stock higher. The stock is likely continuing its momentum after the company secured a U.S. patent fo...
Sellas Life Sciences Group Inc (NASDAQ:SLS) shares are trading higher by 8.3% at $8.24 after the company reported first-quarter EPS results up from last year. Sellas Life Sciences reported quarterly los...
Received $1.0 Million Milestone Payment and Recognized $5.7 Million of License Revenue Under Exclusive License Agreement with 3D Medicines for Development and Commercialization of Galinpepimut-S (GPS) i...
NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer ...
Entered into Exclusive License Agreement, with $7.5 Million Upfront License Fee and Potential to Receive up to an Additional $194.5 Million, with 3D Medicines for Development and Commercialization of Ga...
NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cance...
Shares of SLS stock are up after SELLAS Life Sciences was mentioned heavily on Reddit. Who is this company?
- Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe -
Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are searching for ...
- Early Data from Study of GPS in Combination with Keytruda® in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease Control Rate of 87.5% at a Median Follow-up of 9.4 Weeks and 100% Progression ...
- Proceeds Received from Registered Direct Offering, Warrant Exercises and Upfront Fee from China Out-licensing -
NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of nove...
Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant reduction...
– Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment –
SLS stock is surging today as investors grow interest in a cancer vaccine from SELLAS Life Sciences in the wake of a rally in GLSI stock. The post SLS Stock: Why SELLAS Life Sciences Is Surging Today ap...
- SELLAS to Potentially R eceive Up To $ 202 Million, Inclusive of $7.5 Million Upfront License Fee and $ 8 Million Near-term Milestone s, plus Tiered Royalties -
- Received IM PD A pproval to C ommence E nrollment in France for P ivotal Phase 3 S tudy of G alinpepimut -S in A cute M yeloid L eukemia P atients -
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS ) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
- Strengthened balance sheet in August 2020 with $9.2 million private placement priced at-the-market - - Clinical programs for galinpepimut-S, including phase 3 REGAL study, on track, with multiple da...
Proceeds to be used to fund the ongoing Phase 3 Acute Myeloid Leukemia REGAL study Proceeds to be used to fund the ongoing Phase 3 Acute Myeloid Leukemia REGAL study
NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of nov...
Ongoing Clinical Trials Continue to Progress Ongoing Clinical Trials Continue to Progress
NEW YORK, April 28, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of n...
NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of n...
Preliminary data show 11-fold increase in CD8 cytotoxic T-lymphocytes immune response in patients who received single dose of NPS compared to baseline Preliminary data show 11-fold increase in CD8 cytot...
NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of n...
SELLAS Positive Trial Data, And Other News: The Good, Bad And Ugly Of Biopharma
- Final analysis shows statistically significant median overall survival of 21 months in patients who received GPS compared to previously reported 5.4 months in the control arm (p-value < 0.02) -
Regulatory clarity on registration-enabling Phase 3 study design of NPS in combination with trastuzumab in TNBC patients in the adjuvant setting enhances business development efforts Regulatory clarity ...
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of no...
- Former Klus Pharma and Actinium Pharmaceuticals Executive Brings Extensive Clinical Development Experience in Hematology-Oncology - - Former Klus Pharma and Actinium Pharmaceuticals Executive Brings E...
NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of no...
-- Study Open for Enrollment and Patient Screening Underway -- NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage cli...
- Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on November 8, 2019 - - Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on November 8, 2019 -
About SLS
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b c... [Read more...]
| Industry Biotechnology | Founded 2012 |
| Stock Exchange NASDAQ | Ticker Symbol SLS |
Analyst Forecasts
According to 2 analysts, the average rating for SLS stock is "Buy." The 12-month stock price forecast is 18.75, which is an increase of 119.04% from the latest price.